Egetis Therapeutics AB has been the subject of M&A speculation of late but suitors are going to need deep pockets if they want to get hold of the Swedish biotech, as one thwarted potential buyer has just found out.
Having revealed at the end of March that it was in discussions with various groups regarding a potential acquisition," Egetis has now announced that discussions, "which were triggered by an unsolicited approach by an external party," have been terminated
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?